Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inovio Pharmaceuticals

2.27
+0.15007.08%
Post-market: 2.300.0291+1.28%19:51 EDT
Volume:1.17M
Turnover:2.63M
Market Cap:83.25M
PE:-0.73
High:2.33
Open:2.15
Low:2.14
Close:2.12
Loading ...

Inovio Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Inovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate

Benzinga
·
19 Mar

Inovio Pharmaceuticals Inc - on Track to Begin Rolling Submission of Bla in Mid-2025

THOMSON REUTERS
·
19 Mar

Press Release: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dow Jones
·
19 Mar

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Inovio Pharmaceuticals Inc. Stock Rallies 5.2%, Outperforms Competitors

Dow Jones
·
15 Mar

Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
15 Mar

Inovio Pharma Price Target Maintained With a $18.00/Share by Citizens Capital Markets

Dow Jones
·
14 Mar

Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19

MT Newswires Live
·
14 Mar

Promising Developments in Inovio Pharmaceuticals’ DMAb Platform Justify Buy Rating

TIPRANKS
·
14 Mar

Inovio Announces Promising Interim Results From Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (Dmabs) for Covid-19

THOMSON REUTERS
·
14 Mar

Inovio Pharmaceuticals Inc - Dmabs Well-Tolerated With Mild, Temporary Side Effects

THOMSON REUTERS
·
14 Mar

Inovio Pharmaceuticals Inc - Dmab Levels Remain Stable for 72 Weeks in All Participants

THOMSON REUTERS
·
14 Mar

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

PR Newswire
·
14 Mar

Inovio Pharmaceuticals Inc. Stock Falls 5.9%, Underperforms Competitors

Dow Jones
·
14 Mar

Inovio Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
06 Mar

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
05 Mar

Inovio Pharmaceuticals Inc. Stock Sheds 7.1%, Underperforms Competitors

Dow Jones
·
04 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar